Lung Cancer Screening

Abstract

The National Lung Screening Trial demonstrated that lung cancer screening with three annual low-dose computed tomographic scans has the potential to reduce lung cancer–specific mortality by 20% in an older population of heavy smokers. This was a great achievement by the National Lung Screening Trial (NLST) investigators, but this should be viewed as an important first step in an unfinished process. Many major questions remain about how to best realize this mortality reduction in a practical real-world context. Screening for lung cancer will be most effective if it is accompanied by continued research into risk modeling, patient communication strategies, and biomarkers. For clinicians establishing a program of lung cancer screening, we encourage this to be done in a responsible fashion, adhering to practices specified in the design of the NLST, and with careful attention given to proper management of screen-detected abnormalities and maintenance of screening registries.

Keywords

screening - CT scan - lung nodule - lung cancer - mortality

• References

• 1 Aberle DR, Adams AM, Berg CD , et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (5) 395-409
• 2 Aberle DR, Berg CD, Black WC , et al; National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology 2011; 258 (1) 243-253
• 3 Feinstein MB, Bach PB. Epidemiology of lung cancer. Chest Surg Clin N Am 2000; 10 (4) 653-661
• 4 Bach PB, Kattan MW, Thornquist MD , et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003; 95 (6) 470-478
• 5 Cassidy A, Myles JP, van Tongeren M , et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008; 98 (2) 270-276
• 6 Spitz MR, Hong WK, Amos CI , et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99 (9) 715-726
• 7 Tammemägi MC, Katki HA, Hocking WG , et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368 (8) 728-736
• 8 Kovalchik SA, Tammemagi M, Berg CD , et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013; 369 (3) 245-254
• 9 D'Amelio Jr AM, Cassidy A, Asomaning K , et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 2010; 103 (3) 423-429
• 10 Gliklich RE, Dreyer NA. Registries for evaluating patient outcomes: a user's guide. Rockville, MD: US Dept. of Health and Human Services. Public Health Service, Agency for Healthcare Research and Quality; 2007
• 11 Le Marchand L, Hankin JH, Bach F , et al. An ecological study of diet and lung cancer in the South Pacific. Int J Cancer 1995; 63 (1) 18-23
• 12 Gorlova OY, Weng SF, Hernandez L, Spitz MR, Forman MR. Dietary patterns affect lung cancer risk in never smokers. Nutr Cancer 2011; 63 (6) 842-849
• 13 Pande M, Spitz MR, Wu X, Gorlov IP, Chen WV, Amos CI. Novel genetic variants in the chromosome 5p15.33 region associate with lung cancer risk. Carcinogenesis 2011; 32 (10) 1493-1499
• 14 Gao WM, Kuick R, Orchekowski RP , et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005; 5: 110
• 15 Field JK, Brambilla C, Caporaso N , et al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol 2002; 21 (2) 369-373
• 16 Gorlova OY, Amos C, Henschke C , et al. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. Hum Hered 2003; 56 (1-3) 139-145
• 17 Spitz MR, Etzel CJ, Dong Q , et al. An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) 2008; 1 (4) 250-254
• 18 Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317 (7154) 307-312
• 19 Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012; 157 (8) 571-573
• 20 Swensen SJ, Jett JR, Hartman TE , et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235 (1) 259-265
• 21 Henschke CI, Yip R, Yankelevitz DF, Smith JP ; International Early Lung Cancer Action Program Investigators*. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2013; 158 (4) 246-252
• 22 Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest 2013; 143 (3) 672-677
• 23 Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS ; International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355 (17) 1763-1771
• 24 Hassan C, Giorgi Rossi P, Camilloni L , et al; HTA Group. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012; 36 (10) 929-940
• 25 Jacobs PCA, Mali WPTM, Grobbee DE, van der Graaf Y. Prevalence of incidental findings in computed tomographic screening of the chest: a systematic review. J Comput Assist Tomogr 2008; 32 (2) 214-221
• 26 Yu H, Zhao H, Wang LE , et al. An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. DNA Repair (Amst) 2011; 10 (4) 398-407
• 27 Maisonneuve P, Bagnardi V, Bellomi M , et al. Lung cancer risk prediction to select smokers for screening CT—a model based on the Italian COSMOS trial. Cancer Prev Res (Phila) 2011; 4 (11) 1778-1789
• 28 Albert JM. Radiation risk from CT: implications for cancer screening. AJR Am J Roentgenol 2013; 201 (1) W81-7
• 29 Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 2004; 231 (2) 440-445
• 30 McCollough CH, Chen GH, Kalender W , et al. Achieving routine submillisievert CT scanning: report from the summit on management of radiation dose in CT. Radiology 2012; 264 (2) 567-580
• 31 Raff GL. Radiation dose from coronary CT angiography: five years of progress. J Cardiovasc Comput Tomogr 2010; 4 (6) 365-374
• 32 Foy M, Spitz MR, Kimmel M, Gorlova OY. A smoking-based carcinogenesis model for lung cancer risk prediction. Int J Cancer 2012; 129 (8) 1907-1913
• 33 Ebbert JO, Yang P, Vachon CM , et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003; 21 (5) 921-926
• 34 Field M, Mogg K, Bradley BP. Automaticity of smoking behaviour: the relationship between dual-task performance, daily cigarette intake and subjective nicotine effects. J Psychopharmacol 2006; 20 (6) 799-805
• 35 Jorenby DE, Leischow SJ, Nides MA , et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9) 685-691
• 36 Jorenby DE, Hays JT, Rigotti NA , et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 56-63
• 37 Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR ; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1) 64-71
• 38 Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121 (3) 932-941
• 39 Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev 2004; 13 (12) 2126-2132
• 40 Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345 (3) 181-188
• 41 MacMahon H, Austin JHM, Gamsu G , et al; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237 (2) 395-400
• 42 Naidich DP, Bankier AA, MacMahon H , et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013; 266 (1) 304-317
• 43 Lin M, Stewart DJ, Spitz MR , et al. Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011; 32 (7) 1050-1056
• 44 Gould MK, Donington J, Lynch WR , et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e93S-e120S
• 45 Gould MK, Ananth L, Barnett PG ; Veterans Affairs SNAP Cooperative Study Group. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 2007; 131 (2) 383-388
• 46 Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997; 157 (8) 849-855
• 47 Ceniza SV, Balili ER, Canete MTA, Abrigonda JJM, Rafanan AL. A clinical prediction model for estimating the probability of malignancy of a solitary pulmonary nodule in the Philippine setting [abstract]. Chest 2010; 138 (4, Meeting Abstracts) 725A
• 48 Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e166S-e190S
• 49 Alberts WM ; American College of Chest Physicians. Introduction: diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132 (3, Suppl): 20S-22S
• 50 Sigurdson AJ, Jones IM, Wei Q , et al. Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Carcinogenesis 2011; 32 (1) 69-73
• 51 Sox HC. Better evidence about screening for lung cancer. N Engl J Med 2011; 365 (5) 455-457
• 52 Nease Jr DE, Ruffin IV MT, Klinkman MS, Jimbo M, Braun TM, Underwood JM. Impact of a generalizable reminder system on colorectal cancer screening in diverse primary care practices: a report from the prompting and reminding at encounters for prevention project. Med Care 2008; 46 (9) (Suppl. 01) S68-S73
• 53 Ruffin IV MT, Creswell JW, Jimbo M, Fetters MD. Factors influencing choices for colorectal cancer screening among previously unscreened African and Caucasian Americans: findings from a triangulation mixed methods investigation. J Community Health 2009; 34 (2) 79-89
• 54 Ruffin IV MT, Fetters MD, Jimbo M. Preference-based electronic decision aid to promote colorectal cancer screening: results of a randomized controlled trial. Prev Med 2007; 45 (4) 267-273
• 55 Silvestri GA, Nietert PJ, Zoller J, Carter C, Bradford D. Attitudes towards screening for lung cancer among smokers and their non-smoking counterparts. Thorax 2007; 62 (2) 126-130
• 56 Tammemägi MC, Katki HA, Hocking WG , et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368 (8) 728-736
• 57 Chou R, Croswell JM, Dana T , et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155 (11) 762-771
• 58 Andriole GL, Crawford ED, Grubb III RL , et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360 (13) 1310-1319
• 59 Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317 (7154) 307-312
• 60 Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L ; U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151 (10) 727-737 , W237-42
• 61 Greif JM. Mammographic screening for breast cancer: an invited review of the benefits and costs. Breast 2010; 19 (4) 268-272
• 62 Sharaf RN, Ladabaum U. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies. Am J Gastroenterol 2013; 108 (1) 120-132
• 63 Elmunzer BJ, Hayward RA, Schoenfeld PS, Saini SD, Deshpande A, Waljee AK. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2012; 9 (12) e1001352
• 64 Oken MM, Hocking WG, Kvale PA , et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011; 306 (17) 1865-1873